Business Wire

Cargill Earns #1 Global Ranking for Removing Trans Fats From Edible Oils Portfolio

28.5.2025 17:12:00 CEST | Business Wire | Press Release

Share

Cargill earned the top spot on the inaugural Edible Oil Supplier Index 2025, published by global nonprofit Access to Nutrition initiative (ATNi). The ranking recognizes the company’s leadership in removing industrially produced trans-fatty acids* (iTFAs) from its entire edible oils portfolio, even in markets with no regulatory mandate.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528074187/en/

Cargill earned the top spot on the inaugural Edible Oil Supplier Index 2025, published by global nonprofit Access to Nutrition initiative (ATNi)

Cargill’s leadership in this space has made a tangible difference for customers and consumers around the world. Chantilly, a cherished brand in Mexico known for its bakery, pastry and confectionery products, is a standout example. The company credits Cargill as a key ally in helping remove iTFAs from its popular whipping cream recipes.

“Cargill provided the expertise and technology needed to solve crucial challenges such as maintaining the taste and texture our consumers and operators expect, while preserving the functionality suitable for various culinary applications,” said Miriam Leticia Rodriguez Chigora, R&D leader, Chantilly. “It not only highlights Cargill's ability to provide technical support and innovative solutions but also its commitment to consumer health and regulatory compliance.”

These efforts are part of what ATNi evaluated in its first-ever ranking of the eight largest edible oil suppliers. The international nutrition organization assessed the companies on 19 indicators across four categories. Cargill earned the highest overall score, 81.4%, leading across all assessment areas, with the second-highest scoring company achieving just 14.2%.

This recognition builds on a major milestone reached in January 2024, when Cargill became the first — and still only known — global edible oil supplier whose entire portfolio complies with the World Health Organization’s (WHO) recommended limit of no more than two grams of iTFAs per 100 grams of fats and oils in food products — a threshold set to protect public health.

Cargill’s journey began years earlier, well ahead of the WHO’s 2018 REPLACE initiative, which called for the global elimination of industrial trans fats. The company invested millions in capital upgrades, committed thousands of R&D hours and helped hundreds of customers reformulate products. To date, Cargill has helped remove more than 1.5 billion pounds of products containing iTFAs from the global food chain.

“Being recognized by ATNi reinforces our responsibility to lead with purpose — delivering safe, sustainable nutrition through the food and ingredient solutions we provide,” said David VandenEinde, Vice President of R&D for Food North America, Cargill. “This achievement is the result of decades of innovation, close collaboration with customers like Chantilly, and investment in improved edible oil solutions. We will remain fully engaged with food manufacturers and related stakeholders, working together to help pave the way for a healthier and more resilient global food supply.”

According to the WHO’s 2024 progress report, as of the end of 2023, only 53 of the world’s 195 countries — covering just 46% of the global population — had adopted one of WHO’s best practice policies to limit iTFA in foods. That reality puts added meaning to ATNi’s call for other suppliers to “follow Cargill by example.” The company not only drove change within its own operations and with its customers, but it has also worked as a catalyst for global change, actively collaborating with health organizations to share expertise and support policy development in markets where iTFA regulations are still emerging.

# # #

*Industrially produced trans-fatty acids (iTFAs) are created during the partial hydrogenation of vegetable oils but can also be formed by high thermal treatment during edible oil refining. At high levels of consumption, they have been linked to increased risk of coronary heart disease and mortality, prompting the World Health Organization (WHO) to recommend eliminating iTFAs from global food supplies.

About Cargill

Cargill is committed to providing food, ingredients, agricultural solutions, and industrial products to nourish the world in a safe, responsible, and sustainable way. Sitting at the heart of the supply chain, we partner with farmers and customers to source, make and deliver products that are vital for living.

Our approximately 160,000 employees innovate with purpose, providing customers with life’s essentials so businesses can grow, communities prosper, and consumers live well. With 160 years of experience as a family company, we look ahead while remaining true to our values. We put people first. We reach higher. We do the right thing—today and for generations to come. For more information, visit Cargill.com and our News Center.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250528074187/en/

Contacts

media@cargill.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye